ABOS Acumen Pharmaceuticals Inc
Price (delayed)
$0.9008
Market cap
$54.56M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.71
Enterprise value
$48.12M
Highlights
The company's debt fell by 4% YoY
Acumen Pharmaceuticals's net income has plunged by 95% YoY and by 25% from the previous quarter
The company's quick ratio has shrunk by 67% YoY and by 38% QoQ
Key stats
What are the main financial stats of ABOS
Market
Valuations
Earnings
Shares outstanding
60.57M
Market cap
$54.56M
Enterprise value
$48.12M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.3
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$114.02M
Net income
-$102.33M
EBIT
-$98.26M
EBITDA
-$98.08M
Free cash flow
-$86.23M
Per share
Balance sheet
Liquidity
EPS
-$1.71
EPS diluted
-$1.71
Free cash flow per share
-$1.44
Book value per share
$3.03
Revenue per share
$0
TBVPS
$3.98
Total assets
$238.99M
Total liabilities
$57.18M
Debt
$29.42M
Equity
$181.82M
Working capital
$150.7M
Debt to equity
0.16
Current ratio
6.46
Quick ratio
6.22
Net debt/EBITDA
0.07
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-37.4%
Return on equity
-45.2%
Return on invested capital
-41%
Return on capital employed
-46.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ABOS stock price
How has the Acumen Pharmaceuticals stock price performed over time
Intraday
-8.08%
1 week
-11.69%
1 month
-29.63%
1 year
-74.04%
YTD
-47.63%
QTD
-18.11%
Financial performance
How have Acumen Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$114.02M
Net income
-$102.33M
Gross margin
N/A
Net margin
N/A
Acumen Pharmaceuticals's net income has plunged by 95% YoY and by 25% from the previous quarter
Acumen Pharmaceuticals's operating income has shrunk by 86% YoY and by 23% QoQ
Growth
What is Acumen Pharmaceuticals's growth rate over time
Valuation
What is Acumen Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.3
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Acumen Pharmaceuticals's EPS has plunged by 58% YoY and by 24% from the previous quarter
The P/B is 57% less than the last 4 quarters average of 0.7
The company's equity fell by 32% YoY and by 16% QoQ
Efficiency
How efficient is Acumen Pharmaceuticals business performance
ABOS's return on equity has dropped by 93% year-on-year and by 37% since the previous quarter
ABOS's ROA has dropped by 72% year-on-year and by 34% since the previous quarter
ABOS's ROIC is down by 33% from the previous quarter and by 27% YoY
Dividends
What is ABOS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ABOS.
Financial health
How did Acumen Pharmaceuticals financials performed over time
The company's quick ratio has shrunk by 67% YoY and by 38% QoQ
ABOS's current ratio has dropped by 66% year-on-year and by 38% since the previous quarter
The company's debt is 84% lower than its equity
The debt to equity has grown by 45% YoY and by 14% from the previous quarter
The company's equity fell by 32% YoY and by 16% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.